BioSpace News Archive

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced will host a shareholder update call on Wednesday, April 28, 2021 at 4:30 pm ET.

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated specialty pharmaceutical company, announced today successful results from its initial Pharmacokinetics (PK)/bioequivalence studies. CURE will now advance its clinical program with the objective of U.S. Food and Drug Administration (FDA) approval.

American Lung Association’s ‘State of the Air’ report finds air quality worsened by climate change, remains environmental justice issue

Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced that its Secure Systems Research Centre (SSRC) has partnered with Khalifa University, Georgia Institute of Technology, Tampere University and University of Applied Sciences and Arts of Southern Switzerland (SUPSI).

Red One Medical, a proven government contractor providing best-in-class medical supplies to the VA and DoD, is proud to exclusively partner with Quick Tube Medical to deliver its one-of-a-kind, FDA-registered standardized chest tube systems to special ops units, conventional military forces, first responders and VA hospitals

Chronic obstructive pulmonary disease (COPD) patients for whom a dry powder inhaler device is preferred, can now benefit from an extrafine formulation fixed triple combination therapy containing an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA) / long-acting muscarinic antagonist (LAMA) in a single device. With this new European authorization, Chiesi reinforces its commitment to providing a broad portfolio of formulations and devices to COPD patients. PARMA, Italy, April 21,

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the appointment of Kevin Moulder, PhD, as the Company’s Chief Scientific Officer (CSO).

Sotirios Karathanasis, Ph.D. brings broad drug discovery and development expertise to advance a pipeline of next-gen small molecules discovered by the Enveda platform.

Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve diagnostic testing, is announcing today that it has been awarded a contract from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx SM ) Initiative for $8.2 million

Ambys Medicines, a cell and gene therapy company focused on advancing novel treatments to restore and regenerate liver function, announced today the appointment of Alan Smith, Ph.D., as the company’s new Chief Technology Officer.